Ophiomics was been awarded a funding by the program EIC Accelerator to take our research on hepatocellular carcinoma (HCC) – the leading cause of cancer related mortality world-wide – to the market.
This funding will contribute to speed up the clinical validation and optimization of the Ophiomics product HepatoPredict, a powerful predictive tool to provide decision support in successful liver transplantation. With this, Ophiomics will be able to complete the industrialization of HepatoPredict, achieving all regulatory needs, and commercialize it to global markets.
The awarded funding reflects the innovative nature of HepatoPredict and consolidates Ophiomics as one of the most important stakeholders in the development of solutions for HCC.
EIC Accelerator is a highly competitive grant and equity funding opportunity, that is part of the European Horizon 2020 program. It supports top-class innovators, entrepreneurs, small companies and scientists with funding opportunities and acceleration services, with the purpose of bringing onto the market new innovative products, services and business models that could drive economic growth.
Ophiomics has applied to the April 2019 call, being one of the few awarded companies out of a success rate of 4,44% at the European level.
Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality world-wide. The best curative treatment option is liver transplantation. The need for liver transplants for HCC by far exceeds the number of available organs, so stringent selection criteria are of paramount importance in order to ensure that the best candidates are selected for the procedure. So far, clinicians have to rely only on clinical variables to select transplant candidates
for liver transplantation. The current criteria used (MILAN and San Francisco criteria) limits transplant to patients within specific parameters as tumour number and diameter, clearly related to disease and tumour biological behavior, but can only act as surrogate markers of tumour stage and biology. Hence, it is not possible to predict which patients outside the Milan or San Francisco criteria that would have a favourable prognosis.
On this background, it is of outmost importance to gain access to better predictive tools that can provide decision support in selection for these patients. In response to this challenge, Ophiomics has developed a powerful predictive tool (HepatoPredict) based
on molecular signature and clinical parameters, rather than only clinical variables. We can predict the good outcome
of the intervention with a successful-curative rate of 95%, improving the Milan and San Francisco criteria (67%).
Unsuccessful liver transplantation will be avoided and, as a consequence, better survival rate and more saved lives will be achieved. Upon 5 years after the completion of the project, HepatoPredict will boost the growth of our company generating additional 27 employees and a ROI of 13.82. With the help of SME instrument, Ophiomics aims to complete the clinical validation and product optimization so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the HCC patient ́s quality of life.
PROJECT NAME: HepatoPredict, A decision tool for Liver Transplantation based on molecular signature
GRANT AGREEMENT ID: 946364
START DATE: 01/05/2020 END DATE: 30/04/2022
FUNDED UNDER: H2020-EIC-SMEInst-2018-2020-3
OVERALL BUDGET: 1.912.700,00€
EU CONTRIBUTION: 756.956,38€